Discussing patient priorities for ALS research

Pamela Shaw, DBE, MBBS, MD, FRCP, FMedSci, FAAN, FANA, FAAAS, University of Sheffield, Sheffield, UK, discusses her patients’ priorities for amyotrophic lateral sclerosis (ALS) research. Namely, patients often fear the speed at which ALS progresses and as such are hopeful for effective disease-modifying therapies that can prevent or slow disease progression. Additionally, patients value the efficient progression of promising therapies through the regulatory process. This interview took place at the 18th Annual Congress on Controversies in Neurology (CONy 2024) in London, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.